Fapon Biopharma Reports the US FDA Approval of IND Application for FP008 to Treat Solid Tumors
Shots:
- The company received the US FDA’s approval on the IND application of FP008 to treat pts with solid tumors refractory to anti-PD-1 therapy
- FP008 exhibited safety, PK, and developability in cynomolgus monkey; currently seeking global strategic partnerships to co-develop FP008 through clinical trials & commercialization
- FP008 is an anti-PD-1×IL-10M fusion protein with a unique mechanism and potential for anti-PD-1 naïve or resistant pts
Ref: Prnewswire | Image: Fapon Biopharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
